- Latest week
- 9 Oct 2026
- Weekly close
- 96.96 USD
- Fair value
- 100.51 USD
Seven-day news read · 6–12 October 2026
Recent company news leans cautious
Negative company coverage has outnumbered positive coverage across the last seven days.
Company-specific coverage
The news behind the seven-day read
Newest first. The seven-day balance describes these headlines; the weighted score uses a longer 30-day evidence window.
- 24/7 Wall St. · Main companyModerna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
- Yahoo! Finance Canada · Main companyBioNTech SE (BNTX) Stock Price, News, Quote & History
- The Motley Fool · Main companyBioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
- Simply Wall Street · Main companyIs BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of €2,650.0 Million And Losses?
- Stock Titan · Main companyUnder a prearranged trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 24,000 shares.
- Simply Wall St. · Main companyIs BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?
- marketscreener.com · Main companyBioNTech SE : Gets a Buy rating from Berenberg
- www.marketscreener.com · Main companyBiontech Insider Sold Shares Worth $9,033,642, According to a Recent SEC Filing
Keep the two readings separate
Recent news shows what changed; the score shows the wider tone
A simple description of company headlines published during 6–12 October 2026.
A 30-day reading that gives more weight to newer, directly relevant coverage.